CALGB 8811 regimen
| . | Method . | Dose . | Day . |
|---|---|---|---|
| Induction (4 wk) | |||
| Cyclophosphamide | IV | 1200 mg/m2 | 1 |
| Daunorubicin* | IV | 45 mg/m2 | 1, 2, 3, |
| Vincristine | IV | 2 mg | 1, 8, 15, 22 |
| Prednisone | PO/IV | 60 mg/m2 per day | 1-21 |
| l-asparaginase | SC | 6000 IU/m2 | 5, 8, 11, 15, 18, 22 |
| Early intensification (4 wk—repeat once) | |||
| Intrathecal methotrexate | 15 mg | 1 | |
| Cyclophosphamide | IV | 1000 mg/m2 | 1 |
| 6-mercaptopurine | PO | 60 mg/m2 per day | 1-14 |
| Cytarabine | SC | 75 mg/m2 per day | 1-4, 8-11 |
| Vincristine | IV | 2 mg | 15, 22 |
| l-asparaginase | SC | 6000 IU/m2 | 15, 18, 22, 25 |
| CNS prophylaxis and interim maintenance | |||
| Cranial irradiation | 2400 cGy | 1-12 | |
| Intrathecal methotrexate | 15 mg | 1, 8, 15, 22, 29 | |
| 6-mercaptopurine | PO | 60 mg/m2 per day | 1-70 |
| Methotrexate | PO | 20 mg/m2 | 36, 43, 50, 57, 64 |
| Late intensification (8 wk) | |||
| Doxorubicin | IV | 30 mg/m2 | 1, 8, 15 |
| Vincristine | IV | 2 mg | 1, 8, 15 |
| Dexamethasone | PO | 10 mg/m2 per day | 1-14 |
| Cyclophosphamide | IV | 1000 mg/m2 | 29 |
| 6-thioguanine | PO | 60 mg/m2 per day | 29-42 |
| Cytarabine | SC | 75 mg/m2 per day | 29-32, 36-39 |
| Long-term maintenance (until 24 mo from diagnosis) | |||
| Vincristine | IV | 2 mg | 1 of every 4 wk |
| Prednisone | PO | 60 mg/m2 per day | 1-5 of every 4 wk |
| Methotrexate | PO | 20 mg/m2 | 1, 8, 15, 22 |
| 6-mercaptopurine | PO | 60 mg/m2 per day | 1-28 |
| . | Method . | Dose . | Day . |
|---|---|---|---|
| Induction (4 wk) | |||
| Cyclophosphamide | IV | 1200 mg/m2 | 1 |
| Daunorubicin* | IV | 45 mg/m2 | 1, 2, 3, |
| Vincristine | IV | 2 mg | 1, 8, 15, 22 |
| Prednisone | PO/IV | 60 mg/m2 per day | 1-21 |
| l-asparaginase | SC | 6000 IU/m2 | 5, 8, 11, 15, 18, 22 |
| Early intensification (4 wk—repeat once) | |||
| Intrathecal methotrexate | 15 mg | 1 | |
| Cyclophosphamide | IV | 1000 mg/m2 | 1 |
| 6-mercaptopurine | PO | 60 mg/m2 per day | 1-14 |
| Cytarabine | SC | 75 mg/m2 per day | 1-4, 8-11 |
| Vincristine | IV | 2 mg | 15, 22 |
| l-asparaginase | SC | 6000 IU/m2 | 15, 18, 22, 25 |
| CNS prophylaxis and interim maintenance | |||
| Cranial irradiation | 2400 cGy | 1-12 | |
| Intrathecal methotrexate | 15 mg | 1, 8, 15, 22, 29 | |
| 6-mercaptopurine | PO | 60 mg/m2 per day | 1-70 |
| Methotrexate | PO | 20 mg/m2 | 36, 43, 50, 57, 64 |
| Late intensification (8 wk) | |||
| Doxorubicin | IV | 30 mg/m2 | 1, 8, 15 |
| Vincristine | IV | 2 mg | 1, 8, 15 |
| Dexamethasone | PO | 10 mg/m2 per day | 1-14 |
| Cyclophosphamide | IV | 1000 mg/m2 | 29 |
| 6-thioguanine | PO | 60 mg/m2 per day | 29-42 |
| Cytarabine | SC | 75 mg/m2 per day | 29-32, 36-39 |
| Long-term maintenance (until 24 mo from diagnosis) | |||
| Vincristine | IV | 2 mg | 1 of every 4 wk |
| Prednisone | PO | 60 mg/m2 per day | 1-5 of every 4 wk |
| Methotrexate | PO | 20 mg/m2 | 1, 8, 15, 22 |
| 6-mercaptopurine | PO | 60 mg/m2 per day | 1-28 |
In CALGB 19802, the basic treatment backbone was modified to introduce higher doses of daunorubicin, cytarabine, and systemic methotrexate. The changes in cumulative doses are reflected in Tables 4 and 5.
IV indicates intravenous; PO, oral; and SC, subcutaneous.